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Abstract This Galician consensus statement is a joint
oncologists/cardiologists initiative indented to establish
basic recommendations on how to prevent and to manage
the cardiotoxicity in breast cancer with the aim of ensuring
an optimal cardiovascular care of these patients. A clinical
screening of the patients before treatment is recommended
to stratify them into a determined risk group based on their
intrinsic cardiovascular risk factors and those extrinsic
arose from breast cancer therapy, thereby providing indi-
vidualized preventive and monitoring measures.
Suitable initial and ongoing assessments for patients with
low and moderate/high risk and planned treatment with
anthracyclines and trastuzumab are given; also, measures
aimed at preventing and correcting any modifiable risk
factor are pointed out .
Keywords Cardiotoxicity  Breast cancer  Anticancer
therapies  Cardiovascular risk factors
Introduction and methodology of Consensus
Meeting
Improved survival of cancer patients in recent decades,
together with the toxicities of antitumor drugs, the
increased population of patients over 65 years (with
comorbidities), and an inadequate knowledge and man-
agement of risk factors, has led to an increase in car-
diovascular morbidity in cancer patients [1].
Chemotherapy is a cardiovascular risk factor, even more
with radiotherapy, increasing by 30% the incidence of
events compared to the general population [2]. Consid-
ering the high frequency of cardiovascular risk factors and
the presence of preexisting cardiovascular disease, it is of
key importance to optimize and standardize the manage-
ment of these patients, in a multidisciplinary approach
that we could call Cardio-Oncology [1]. Breast cancer
was chosen for this consensus because of its incidence
and high survival rates, which grants greater importance
to prevention, control and monitoring of toxicity, and
because of the routine use of radiotherapy and cardiotoxic
drugs. With this purpose, the following methodology was
applied: first, one cardiologist presentation; followed by
two workshops (medical oncologists), with discussion and
conclusions of each one; followed by sharing perspectives
on key issues and consensus; and finally, manuscript
drafting and review.
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• To establish the clinical cardiovascular risk factors and
those intrinsic to treatment in breast cancer patients.
• To establish the basis for prevention of cardiotoxicity
related to anticancer treatments for breast cancer.
• To establish multidisciplinary cardio-oncological bases
for early intervention in the management of
cardiotoxicity.
• Finally, to establish basic recommendations agreed by
consensus for prevention, initial management, and
referral.
The cardiologist’s viewpoint
Cardiac dysfunction related to cancer treatment has been
defined as a decrease in left ventricular ejection fraction
(LVEF) by ultrasound greater than 10% (from baseline)
and with an absolute value less than 53%, confirmed by a
repeat examination at 2–3 weeks [3]. LVEF between 53
and 73% is considered normal. At least two types of
mechanisms of cardiotoxicity are recognized, according to
the presence or not of structural anomalies and their
reversibility [4]. In type I (adriamycin model), myocardial
cell necrosis/apoptosis occurs in a dose-dependent manner,
causing permanent damage (visible on biopsy), and for
which early diagnosis, prevention, and treatment are
essential. In type II (trastuzumab model), cellular dys-
function without apparent structural damage occurs, due to
blockade of cellular survival pathways associated with
HER2 and activated by stress, there appears to be no
cumulative effect, and the damage is reversible in the
majority of cases with drug discontinuation [5]; and for its
prevention, the knowledge of risk factors and monitoring of
treatment are very important. It should be noted that car-
diotoxicity is potentiated by the combination of anthracy-
clines and trastuzumab [6]. Nevertheless, the finding on
cardiac magnetic resonance imaging (MRI) of scars in
patients with type II toxicity, as well as the improvement in
cardiac function with adequate early treatment in some
type I cases [7], indicates that this classification may not be
so strict. Moreover, while anthracyclines and anti-HER2
agents make up the two large groups of cardiotoxic drugs,
other cytotoxic drugs, other monoclonal antibodies, and
certain tyrosine-kinase inhibitors and antiangiogenic drugs
may also be cardiotoxic through different mechanisms.
Cardiac damage initially occurs in a molecular phase,
followed by cellular damage, asymptomatic dysfunction,
and finally symptomatic clinical dysfunction. Our diag-
nostic intervention is currently based on monitoring LVEF
by ultrasound, multigated acquisition (MUGA) scan or
MRI, considering\53% as abnormal. Although the refer-
ence technique for quantification of LVEF is cardiac MRI,
ultrasound offers the advantages of its availability, low
cost, lack of radiation, and overview of cardiac function.
However, 2D ultrasound depends on the quality of the
image and the expertise of the operator. Furthermore, it has
a reported variability of about 10%, similar to the value
used for diagnosis of cardiotoxicity. New non-enhanced 3D
imaging techniques reduce this variability and are consid-
ered the ideal method for monitoring patients treated with
cardiotoxic drugs [8].
However, the measurement of LVEF is able to diagnose
and quantify but does not predict the development of car-
diotoxicity. We need other parameters to detect early
changes predictive of late morbidity and mortality. The
cardiac muscle is formed by three layers of myocardial
fibers with different orientations, and systolic function of
the left ventricle is the sum of longitudinal contraction,
circumferential shortening, and radial thickening. Mea-
surement of LVEF only evaluates radial function [9, 10].
New imaging techniques can provide information in earlier
stages. The most widely used are those quantifying
myocardial deformation, and the most studied parameter is
deformation of longitudinal fibers or global longitudinal
strain (GLS). Its normal value in healthy subjects is
-19.7%, with less than 4% of variability [11–13]. A
review (n = 384) showed that GLS changes are frequent
during treatment with anthracyclines and occur earlier than
LVEF changes [14]. In addition, cardiac biomarkers (ba-
sically troponins) are also a useful tool in monitoring of
cardiotoxic treatments. They are simple to use and have
very low variability between determinations [15, 16]. Thus,
a 10–15% early reduction in GLS combined with a rise in
troponins has been shown as a good predictor of clinical
events or ventricular dysfunction. If GLS and troponins are
normal at 6 months after completing treatment, the risk of
dysfunction is low, which shows that the combination of
these parameters has a high predictive value [14].
Despite the above, only 30–35% of patients receiving
cardiotoxic therapies who present with asymptomatic left
ventricular dysfunction receive beta-blockers (BB) or
angiotensin-converting-enzyme inhibitors (ACEIs)/an-
giotensin II receptor antagonists (ARA II); and only about
40% receive a cardiological consultation [17]. Manage-
ment of these patients should be performed according to
current cardiological guidelines, such as the ACCF/AHA
guideline [18]. When these patients are referred for cardi-
ology consultation, prescription of ACEIs and BBs
increases along with survival [19]. It is important to note
that when dysfunction develops, the probability of com-
plete recovery is reduced despite optimal treatment [7]. But
it should also be stressed that early intervention can stop
damage progression and improve cardiac function. It has
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been estimated that 40–55% of patients can normalize
their LVEF even after having developed clinical car-
diotoxicity [20]. The efficacy of ACEIs (enalapril type) as
first-line treatment has been shown in breast cancer
patients after anthracycline-based chemotherapy, by
improving cardiac function [21]. BBs (carvedilol or
bisoprolol type) are the second essential drugs, and
combined carvedilol and enalapril in low doses has
demonstrated its utility, too [7]. In this way, ACEIs/ARA
II and/or BBs have already shown that enhances recovery
of LVEF and improves cardiovascular prognosis [22]. The
key is the earliness of the start of treatment. So, delays
greater than 6 months considerably reduce the chances of
success. Once LVEF falls below 53%, even in the absence
of symptoms, it is recommended to start early treatment
with progressively higher doses according to clinical
tolerance [8]. In addition, early intervention to promote
cardio-healthy lifestyle habits and to control existing
cardiovascular risk factors is also essential. The goals are
to maintain a body mass index (BMI) between 18 and 25,
not to smoke, do exercise, maintain low-density lipopro-
tein (LDL) cholesterol levels below 100 and glycated
hemoglobin (HbA1c) levels below 7%, and to control
arterial hypertension, if appropriate [23]. Finally,
depending on its course, reversibility can now be classi-
fied into four groups: reversible, if LVEF improves more
than 10% with a difference from baseline B5%; partially
reversible, if LVEF improves but differences persist with
baseline[5%; irreversible, if LVEF improves less than
10% and maintains differences with baseline[5%; and
indeterminate if no follow-up is performed).
In summary, early prevention of cardiotoxic events in
patients undergoing cancer treatment is essential. There-
fore, and to minimize the cardiotoxicity of treatment as far
as possible, risk should be evaluated individually, identi-
fying and controlling cardiovascular risk factors, and
thereby permitting early diagnosis and treatment. The
objective initially will be to detect which patients are at
risk of developing stage B heart failure (Fig. 1) and to
intervene actively both in lifestyle modification and control
of cardiovascular risk factors.
Workshop 1: Cardiological risk factors of patients
undergoing breast cancer treatment
• Age: extreme ages, very young or C65–70 years, are a
risk factor. In a retrospective study it was observed that
the risk of suffering heart failure (HF) due to anthra-
cyclines increased with age [24]. Other retrospective
study showed a 2.25-fold higher risk of HF after a total
adriamycin dose of 400 mg/m2 in patients older versus
younger than 65 years [25]. Similarly, age[65 years
has been related to an increased risk (HR 2.08) of
cardiotoxicity with trastuzumab in a retrospective
analysis [26].
• Gender: being a woman, especially postmenopausal, is
a risk factor; although it is controversial in cancer
treatment because the literature offers contradictory
results. In long-term follow-up studies of childhood
cancer survivors treated with anthracyclines, greater
cardiotoxicity was observed in women [27]. However,
in a study of adult patients with lymphoma, male
gender was correlated to greater cardiotoxicity than
female [28].
• Smoking: the relationship between smoking and heart
disease is widely documented.
• Sedentarism: it is also an important cardiovascular risk
factor, considered as less than 150 min per week of
moderate exercise.
• Obesity: the presence of a BMI C25 is also considered
a risk factor. Weight C70 kg has been identified as
predictive factor for cardiotoxicity in advanced breast
cancer treated with anthracyclines [29]. A BMI C27
has also been correlated to an increased incidence of
cardiac dysfunction in patients with adjuvant epiru-
bicin-based chemotherapy versus a BMI\27 (1.8 vs
0.9%) [30]. These results could be explained at least in
part by the fact that obese patients received higher
doses of anthracyclines if calculated by their real body
surface.
• Diabetes mellitus (DM): it is also a well-documented
cardiovascular risk factor.
• Dyslipidemia: total cholesterol/LDL-cholesterol ratio is
another well documented risk factor.
• Arterial hypertension (HT): control of blood pressure
reduces the HF risk by over 50% [31, 32]. It should be
performed according clinical guidelines [18]. A meta-
analysis has suggested that diuretics, ACEIs and ARA-
II are the most effective drugs [32].
• Preexisting cardiovascular disease: It is common that at
time of diagnosis, breast cancer patients already have
risk of developing a cardiovascular disease, which will
be increased by the effect of treatment, in what is
known as the ‘‘multiple-hit’’ hypothesis [33]. Further-
more, it has been reported that a previous cardiovas-
cular disease increases the risk of developing HF after
anthracyclines, with a HR for myocardial infarction or
atherosclerosis of 2.21 and of 1.53 for any other
previous cardiovascular disease [34].
Based on these factors we finally established two large risk
groups:
– Low risk: asymptomatic patients without risk factors.
– Moderate/high risk, with [5% of cardiac events at
10 years: presence of C2 factors listed above.
Clin Transl Oncol
123
Workshop 2: cardiotoxicity risk factors related
to breast cancer treatment
• Local treatment: chest wall/mediastinal irradiation:
Radiotherapy affects the heart at various levels:
valvular, vascular, pericardium, and myocardium,
especially if 30 Gy are exceeded [1, 35] and/or the
internal mammary chain is irradiated. The incidence of
cardiotoxicity related to irradiation is estimated to be
10–30% in the 5–10 years following treatment [36].
Moreover, damage caused by anthracyclines is more
common in previously radiated patients [37]. A ran-
domized study with adriamycin with or without radio-
therapy showed an increase in cardiac events with
doses over 450 mg/m2 and radiotherapy [38]. However,
with modern planning and techniques, irradiation of
cardiac structures can be reduced to a minimum.
• Cytotoxic systemic treatment: anthracyclines: Anthra-
cyclines have the highest rate of acute (myopericarditis,
arrhythmias) and chronic cardiac toxicity. They asso-
ciate with a risk of irreversible progressive cardiomy-
opathy of 3–26%. In a meta-analysis (22,815 patients),
adriamycin were associated with a 6 and 18% risk of
clinical and subclinical cardiotoxicity, respectively; a
10% rate of events; and a 0.4% of deaths of cardiac
origin [39]. Their risk is clearly related to the cumu-
lative dose. Thus, HF risk with a standard regimen
(bolus dose every 3 weeks) and a cumulative
dose\ 300 mg/m2 is about 2%, although this risk
begins to significantly increase from 300 mg/m2 [6].
Their cardiac toxicity also depends on the frequency of
administration and of rate of infusion. Thus, 6 h or
longer infusions or weekly schedules show less car-
diotoxicity than standard boluses, by avoiding high
plasma peaks [37]. And, of course, their toxicity is
increased in presence of radiotherapy and other
cardiovascular risk factors, including the use of other
cardiotoxic drugs such as taxanes or trastuzumab. In
addition to adriamycin, there are available other
anthracyclines. Epirubicin is an epimer of adriamycin
apparently less cardiotoxic, at least when it is used in
equivalent myelosuppressive doses of up to
700–800 mg/m2. Its incidence of cardiomyopathy is
of 1–3%. A study showed a 1.9% risk with doses of up
to 800 mg/m2, increasing to 4.3% with 900 mg/m2
[40]. These data are similar to those reported with
adriamycin, so probably the difference is simply that
cardiotoxic doses are not usually reached with epiru-
bicin. There are also studies in which concomitant
trastuzumab–epirubicin (FEC) is highly effective in
HER2? breast cancer treatment, without relevant
cardiotoxicity at the doses used [41].
Liposomal anthracycline formulations are clearly less
cardiotoxic as has been demonstrated in at least three
randomized studies. They were developed to improve
the therapeutic index of conventional anthracyclines.
Liposomal encapsulation prevents its extravasation into
capillaries of cardiac muscle, facilitating its passage
Fig. 1 Adapted ACCF/AHA 2013 guideline for the management of heart failure. HT hypertension, LV left ventricular
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into immature vascular systems (tumor vessels),
reduces its volume of distribution and diffusion, and
also reduces plasma peaks. So, maintaining its antitu-
mor activity toxicity is generally lower in healthy
tissues [42]. There are two liposomal-encapsulated
formulations of adriamycin, pegylated (PLA,
CAELYX) and non-pegylated (NPLA, MYOCET).
The latter has a reduced myocardial uptake and rapid
clearance, preventing the occurrence of toxic peaks.
Both were at least as effective as conventional
adriamycin in first-line treatment of advanced breast
cancer. Thus, a randomized study showed equivalent
efficacy and reduced cardiotoxicity (4 vs 19%) of PLA
versus adriamycin, with increased hand-foot syndrome
(HFS) [43]. Two randomized trials showed that NPLA
is significantly less cardiotoxic than conventional
adriamycin (13 vs 29% in one trial, and 6 vs 21% in
the other trial), with comparable efficacy [44, 45], with
a trend to reduced gastrointestinal toxicity and neu-
tropenia, and negligible HFS [46]. A pooled analysis
from these two trials has suggested that NPLA could be
even more effective than conventional adriamycin, in
terms of response rate (31 vs 11%) and progression-free
survival (PFS) (4.2 vs 2.1 months) [42]. Finally, a
meta-analysis showed significantly lower rates of both
clinical (RR 0.20) and subclinical heart failure (RR
0.38) with NPLA compared with adriamycin [46].
Based on the above, liposomal anthracyclines are a
reasonable alternative in patients with anthracycline
therapy indication and increased cardiac risk. This
would include having received adjuvant anthracycline
therapy at dangerous cumulative doses.
• Cytotoxic systemic treatment: other cytotoxic agents:
Cyclophosphamide: Cyclophosphamide acute car-
diotoxicity (myocardiopericarditis) is generally related
to high doses and usually resolve without sequelae after
discontinuing the drug. Taxanes: Paclitaxel has been
related to disturbance in cardiac rhythm, mainly
episodes of acute symptomatic bradycardia, and when
used in combination with adriamycin it has been shown
to increase the cardiotoxicity of the latter in a sequence-
dependent manner, so the administration should be
paclitaxel first, followed by adriamycin [47]. Other
cytotoxic agents: in addition to the vascular toxicity
(ischemia) of the fluoropyrimidines, different inci-
dences of cardiomyopathy have been reported with
ifosfamide, cisplatin, and vincristine.
• Endocrine systemic treatment: estrogens have benefi-
cial effects on lipids in postmenopausal women, so
estrogen cessation could increase cardiovascular risk.
However, the cardiac risk of antiestrogen treatment is
insufficiently studied. In advanced disease, it appears
that ischemic events (1–4%) and arrhythmias (4–7%)
are the most predominant [48]. Tamoxifen has been
related to venous thrombotic events, and it does not
appear to exert a clear cardioprotective effect despite
reducing cholesterol levels. Aromatase inhibitors in
general increase cholesterol levels, at least when
compared to tamoxifen, and some studies have reported
more cardiac events (versus tamoxifen). Nevertheless,
the data in the literature are few, discordant, and
inconsistent.
• Anti-HER2 systemic treatment: Trastuzumab: Tras-
tuzumab, a monoclonal antibody against HER2, is
known to be cardiotoxic, especially in combination
with anthracyclines. In a pivotal trial in advanced
breast cancer, the incidence of HF was 16% in the
Adriamycin (AC) ? trastuzumab arm versus 3% in
the AC arm [49]. As adjuvant therapy, the incidence
of cardiac events was also higher with anthracyclines
plus trastuzumab (4.1%) versus anthracyclines (0.8%)
[50]. A meta-analysis of 11,882 patients showed that
HF risk significantly increased if the patients also
received anthracyclines (RR 4.19 in initial, 4.75 in
advanced disease), but not in those who did not [51].
In the Breast Cancer International Research Group
006 study to evaluate adjuvant trastuzumab, clinical
HF rate was five times lower (0.38 vs 1.96%) when
trastuzumab was used without anthracyclines (doc-
etaxel–carboplatin) [52]. Other adjuvant therapy
study with trastuzumab (n = 1664) showed some
predictors of cardiotoxicity: age, previous cardiovas-
cular conditions, and the characteristics of the
treatment received [53]. Although trastuzumab-in-
duced cardiotoxicity (type II) has not traditionally
been considered as cumulative, in the HERA study
an increased risk of discontinuing treatment due a
cardiac cause was reported in the 2-year trastuzumab
arm versus the 1-year arm [54]. However, after a
median follow-up of 8 years, the incidence of cardiac
events was very low, without differences between the
1- and 2-year arms (0.8%) [55]. Moreover, in the
Finn-HER study, with only 9 weeks of trastuzumab,
cardiotoxicity was minimal [56]. Other anti-HER2
drugs: with different mechanisms of action, per-
tuzumab, trastuzumab-emtansine (T-DM1), and lap-
atinib appear to be less cardiotoxic. In advanced
disease, the incidence of asymptomatic cardiac
events with lapatinib has been reported to be of
1.4%; as for pertuzumab combined with trastuzumab,
a rate of ventricular dysfunction of 8%, mainly
asymptomatic [57] was observed. In the phase III
pivotal study with T-DM1, the reported incidence





It is essential to research on cardiotoxicity of anticancer
agents, primary prevention, and early detection of injury, as
well as monitoring and treatment of early heart damage
[59]. In addition to survival, the goal of oncologists should
be to reduce toxicities, especially late toxicities and par-
ticularly cardiotoxicity. As we have seen, we must to
optimize the strategies to reduce the risk of cardiovascular
events. Once toxicity has occurred, even if asymptomatic,
cardiological assessment is recommended, and a close
structured collaboration between cardiologists and oncol-
ogists should be required [39].
It is possible to calculate, prior to initiating treatment, an
overall risk score of developing cardiotoxicity. This risk
would be the sum of the following points (maximum, 14):
medication risk score (4 points for anthracyclines and
trastuzumab, among others); plus one point for each car-
diovascular risk factor (women, \15 years or over 65,
history of cardiomyopathy or congestive heart failure,
ischemic heart disease, arrhythmias, corrected QT
[500 ms, hypertension, diabetes), previous use of anthra-
cyclines and/or thoracic radiotherapy [1] (Table 1). In this
way, a pyramid can be constructed according to the indi-
vidual risk of each patient. At the base would be patients
with low risk (\65 years, B1 risk factor and good control)
who are asymptomatic and for whom the intervention
would be to optimize lifestyle and control the use of car-
diotoxic agents. At the top would be patients with symp-
tomatic heart disease, with moderate-severe ventricular
dysfunction, in whom the use of cardiotoxic agents should
be avoided. And between both would be patients with
moderate risk ([2 risk factors), asymptomatic but with a
risk of heart disease [5%. In these cases, added to
optimizing lifestyle and controlling risk factors, the inter-
vention should be aimed at adjusting as much as possible
the use of anthracyclines or assessing the need of liposomal
formulations; and in any case, an adequate monitoring of
potentially cardiotoxic treatments to perform early diag-
nosis of injury (Fig. 2) should be established.
There are several algorithms published for monitoring
patients receiving treatment with anthracyclines [60],
trastuzumab [61] (Fig. 3); and radiotherapy [62]. It is
generally recommended to perform a baseline LVEF
assessment in all patients who start a cardiotoxic treatment,
with the frequency of subsequent monitoring depending on
the calculated risk. With anthracyclines, it is generally
recommended to repeat the assessment at the end of
treatment and at 6 months, and if the dose exceeds 300 mg/
m2, before each cycle. For trastuzumab, it is recommended
that assessments are performed every 3 months during
active treatment and at 6 months after the end of treatment
[3]. However, this regimen may be difficult to apply in
clinical practice, so it is advisable for oncology and car-
diology teams of each center to establish a plan of mini-
mum requirements including an early referral path to
cardiologist (Table 2). Diagnosis of cardiotoxicity is cur-
rently made by measurement of LVEF, optimally by 3D
echocardiography. In case of 2D LVEF, use Simpson’s
method ± contrast or MRI when in doubt or before making
changes in treatment due to cardiotoxicity. The ideal
strategy to anticipate risks seems to be changes related to
GLS ± alteration of troponins so that if both are abnormal,
the positive predictive values is 94% (diagnosis), and if
both are normal, the negative predictive value is 97%.
It is known that prevention strategies including cardio-
healthy lifestyle habits (healthy diet, regular exercise,
control of BMI or abdominal fat, avoidance of smoking and
alcohol), as well as control of clinical risk factors
Table 1 Cardiotoxicity risk assessment
Risk of cardiotoxicity related to cancer treatment Criteria for high CV risk of developing cardiotoxicity
High risk
Anthracyclines, cyclophosphamide, ifosfamide, trastuzumab, and clofarabine
Intermediate risk
Docetaxel, pertuzumab, sunitinib, and sorafenib
History of:





Bevacizumab, dasatinib, imatinib, lapatinib, etoposide, rituximab, and thalidomide
HT
Diabetes
Previous use of anthracyclines
Mediastinal radiotherapy
Female gender
\15 years or[65 years
CV cardiovascular, HT hypertension, QTc corrected QT interval
Clin Transl Oncol
123
(hypertension, dyslipidemia, or hyperglycemia), are asso-
ciated with a lower incidence of cardiovascular disease
[63–65]. In this regard, statins in 628 patients with breast
cancer receiving anthracyclines reduced the incidence of
HF [66]. Moreover, atorvastatin has shown cardioprotec-
tion in patients treated with anthracyclines [67]. In a ret-
rospective study on patients with normal LVEF prior to
treatment with anthracyclines and trastuzumab, 106
patients have received beta-blockers (BBs) during
chemotherapy, which was associated with a significant
reduction in HF (HR 0.2) [68]. In a prospective study,
enalapril reduced the incidence of ventricular dysfunction
compared with placebo in patients with troponin elevation
after anthracyclines [69]. The OVERCOME study involved
90 hematological tumor patients and showed that after
6 months of treatment with enalapril plus carvedilol the
incidence of cardiac events significantly decreased [70]. On
the other hand, it has been reported that not all BBs offer
the same protection against cardiotoxicity. Non-selective
BB such as propranolol could even potentiate toxicity [71],
while carvedilol and nebivolol have shown to be protective
[72–75].
Based on the information reviewed above, it is possible
to establish protective strategies for individual risk. The
risk of cytotoxic agents can be prevented by standardized
protection protocols, optimizing their use (schedule,
dosage), and including the option of less cardiotoxic agents
use. To prevent the risk of thoracic irradiation, planning
should be optimized and doses reduced as much as possible
(\30 Gy in total,\2 Gy daily). Regarding individual risk
factors, those that are modifiable include hypertension,
diabetes, dyslipidemia, smoking, sedentarism, and
treatment of heart diseases in general. Aerobic cardiovas-
cular training is fundamental to metabolic control, and a
very effective method to improve quality of life and
capacity of exercise in cancer patients. Furthermore, it has
been published that regular physical activity (3–5 h of
moderate exercise a week, equivalent to walking 30 min at
least 5 days a week) reduces cancer mortality by 30–50%
in patients treated with curative intent [76]. So, it is pos-
sible to establish general recommendations about lifestyle
habits (Table 3). However, age, female sex, and genetic
predisposition are not modifiable factors.
The final objective should be to evaluate individual risk
of cardiotoxicity in each patient, in order to, on the one
hand, apply preventive measures and optimize manage-
ment and control of modifiable risk factors; and on the
other hand, avoid the use of cardiotoxic drugs based on the
risk/benefit assessment or, as alternative, use drugs with
less cardiotoxic profile. Cardioprotective drugs like
dexrazoxane (iron chelator), although they have been
shown to reduce cardiotoxic events [77], are not recom-
mended by the American Society of Clinical Oncology due
to the risk of bone marrow suppression and second cancers,
and especially because of doubts about a reduction in the
efficacy of the cytotoxic agent [78]. Therefore, the best
option, if anthracyclines are indispensable, is the use of
agents with a reduced cardiac toxicity profile, such as
liposomal anthracyclines [79].
Key messages [80]
• Cardiovascular disease is the most common cause of
mortality in patients who have survived a cancer. A
multidisciplinary approach is essential in order not to
compromise the prognosis of these patients.
• Patients treated with potentially cardiotoxic drugs are
encompassed in stage A of heart failure.
• Clinical screening is required before treating patients
with breast cancer to stratify them according to the
calculated risk and to apply adequate preventive and
monitoring measures.
• Early and optimal control of cardiovascular risk factors
is essential to improve the diagnosis. Preliminary
studies support primary preventions with ACEIs
(enalapril), BBs (carvedilol, nebivolol), and/or statins
(atorvastatin).
• It is necessary to optimize the indications of cardiotoxic
agents and to apply preventive measures from the
beginning, which may include the use of cardioprotec-
tive drugs (in very select cases) or liposomal formu-
lations of anthracyclines.
• The current recommendation is to monitor LVEF with
3D echocardiography (2D if not available), together
Fig. 2 Pyramid for management of cardiotoxicity risk. CVRF
cardiovascular risk factors, CV cardiovascular
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with contrast administration in case of a nonoptimal
window. If the assessment is still suboptimal, or before
modifying treatment for ventricular dysfunction, it is
recommended to confirm LVEF by cardiac magnetic
resonance imaging. The use of GLS and high-sensitiv-
ity troponins allows early diagnosis of subclinical
myocardial injury.
• Early treatment of myocardial injury is vital to improve
the cardiovascular prognosis and the quality of life of
survivors. The probability of recovering LVEF depends
primarily on the earliness of treatment.
• Multidisciplinary collaboration by the cardio-oncology
team ensures optimal cardiological care of oncological
patients and increases the safety of treatments.
Consensus recommendations
Individualized initial and ongoing assessment according to
risk factors:
• Established clinical risk group:
– Low risk: asymptomatic patient without risk
factors.
– Moderate/high risk: presence of C2 risk factors
listed in Workshop 1.
• Low risk assessment:
– Planned treatment with anthracyclines, clinical
assessment, baseline ECG and blood tests
Fig. 3 Sample algorithm for
trastuzumab monitoring. (From
The Oncologist [61], with
permission). HF heart failure,




(including fractionated lipid profile and HbA1c),
and LVEF assessment at end of treatment.
– Planned treatment with trastuzumab in addition to
the previous points, a baseline and some interme-
diate LVEF assessment during treatment is
recommended.
• Moderate/high risk assessment:
– planned treatment with anthracyclines, clinical
assessment, baseline ECG and blood tests (includ-
ing fractionated lipid profile and HbA1c), and
LVEF assessment at baseline and the end of
treatment.
– Planned treatment with trastuzumab in addition to
the above, it is recommended with low consensus
level, to adjust the intermediate LVEF monitoring
(every 3–6 months) to existing risk factors and the
decreases observed in previous LVEF
measurements.
– Among attendees there was the idea that in addition
to the above, monitoring of serum levels of high-
sensitivity troponins before each cycle (in centers
Table 2 Monitoring and referral to cardiology
Cardiotoxicity risk Monitoring
High risk drugs ? established heart disease
and LVEF\40%
Carefully assess indication for cardiotoxic agents. Individualize, support from cardiology
High/moderate risk drugs ? CVRF
or LVEF[40%
Baseline: ECG; blood test (HbA1c, lipids and troponin?); LVEF measurement (2D/3D
US ± GLS)
During treatment: control CVRF, troponin in each cycle?; assess BB, ACEIs, and statins
End of treatment: troponin?; ECG, LVEF measurement (2D/3D US ± GLS)
Follow-up: measure LVEF at 6 months from end of treatment (2D/3D US ± GLS), and
every 3–4 years
High/moderate risk drugs ? asymptomatic
without CVRF
Baseline: ECG; blood test (HbA1c, lipids, and troponin?)
End of treatment: troponin?; ECG, LVEF measurement (2D/3D US ± GLS)
Follow-up: according to symptoms
Criteria for referral to cardiology
Patients with high or intermediate risk of cardiotoxicity, to optimize medical treatment: BB, ACEIs, statins
Previous treatment with adriamycin C300 mg/m2
Mediastinal irradiation C30 Gy
Previous heart disease (cardiomyopathy, heart failure, arrhythmias or ischemic heart disease), if not followed up in cardiology
Poorly controlled CVRF with treatment: HT, diabetes, dyslipidemia, smoking
Alterations at baseline: ECG, troponin or LVEF measurement
Alterations during follow-up:
LVEF decrease[10% or LVEF\53%
Abnormal GLS ([-19%) or decrease[15%
Positive troponin I
Chest pain, dyspnea on exertion, syncope, arrhythmias
HT refractory to conventional treatment
ACEIs angiotensin converting enzyme inhibitors, BB beta-blockers, CVRF cardiovascular risk factors, ECG electrocardiogram, GLS global
longitudinal strain, Hb hemoglobin, HT hypertension, LVEF left ventricular ejection fraction
Table 3 Healthy lifestyle recommendations
No smoking
Limit salt and alcohol consumption (1–2 glasses of red wine a day)
Practice exercise: walk 30 min at least 5 days a week
Adopt a Mediterranean diet: 5–6% saturated fat; 26–27% fat; 15–18% proteins; 55–59% carbohydrates
Check weight periodically and consult in case of sudden increases or presence of edema
Control cholesterol, glucose, and blood pressure (\140/85)
Consult in case of shortness of breath or chest pain with exercise, palpitations or blackouts
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where this is available) could optimize follow-up
and improve both prevention and early therapeutic
intervention, but a consensus was NOT reached for
its generalized use. If troponin monitoring is used
and an elevation is observed, an echocardiogram
should be performed and consider, depending on
each case, to start treatment with BB or ACEIs in
order to prevent long-term ventricular dysfunction
and continue cancer treatment.
Individualized and dynamic initial and ongoing
intervention:
• prevention and correction of modifiable risk factors
(Table 3): this requires recommendations not only
involving each patient individually, but all healthcare
personnel intervening in their treatment (nursing, other
specialists, primary care), as well as patient associa-
tions, the media, and in general society as a whole.
• Optimize cardiovascular treatment of these patients. If
drugs for blood pressure control are needed to opt for
ACEIs (e.g., enalapril) and/or BBs (e.g., carvedilol,
nebivolol) and discontinue calcium antagonists, espe-
cially verapamil or diltiazem (negative intropes). With
respect to the use of statins, there is no clear evidence to
start therapy with normal cholesterol levels. The key is
a strict control of LDL levels and to start statins (e.g.,
atorvastatin) with LDL[100 mg/dL.
Referral to cardiologist
It is recommended to provide rapid communication chan-
nels between specialists and to consult cardiologist for
treatment changes. Early treatment of myocardial injury
(with ACEIs and/or BBs) is vital to improve the cardio-
vascular prognosis. Moreover, cardiologist intervention
should be mandatory in case of an abnormal ECG or
baseline measurement of LVEF, a significant decrease in
LVEF during monitoring, a sustained and confirmed poor
blood pressure control ([140/85), and in the presence of
cardiac alarm symptoms or signs such as arrhythmias,
syncope, chest pain, dyspnea, edema, etc.
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